158 related articles for article (PubMed ID: 17553909)
1. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK.
Ara RM; Reynolds AV; Conway P
Rheumatology (Oxford); 2007 Aug; 46(8):1338-44. PubMed ID: 17553909
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.
Neilson AR; Sieper J; Deeg M
Rheumatology (Oxford); 2010 Nov; 49(11):2122-34. PubMed ID: 20660498
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
6. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
Wailoo A; Bansback N; Chilcott J
Rheumatology (Oxford); 2008 Feb; 47(2):119-20. PubMed ID: 18208819
[No Abstract] [Full Text] [Related]
7. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
[TBL] [Abstract][Full Text] [Related]
9. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.
Tran-Duy A; Boonen A; van de Laar MA; Franke AC; Severens JL
Ann Rheum Dis; 2011 Dec; 70(12):2111-8. PubMed ID: 21857027
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.
Jansen JP; Pellissier J; Choy EH; Ostor A; Nash JT; Bacon P; Hunsche E
Curr Med Res Opin; 2007 Dec; 23(12):3069-78. PubMed ID: 17971283
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
[TBL] [Abstract][Full Text] [Related]
12. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
Larsen CG; Andersen PH; Lorentzen H; Zachariae C; Huldt-Nystrøm T; Dotterud LK; Lindkvist RM; Qvitzau S
Eur J Dermatol; 2013; 23(6):774-81. PubMed ID: 24334009
[TBL] [Abstract][Full Text] [Related]
14. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
Villacorta R; Hay JW; Messali A
Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
[TBL] [Abstract][Full Text] [Related]
16. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model.
Le QA; Kang JH; Lee S; Delevry D
J Manag Care Spec Pharm; 2020 Oct; 26(10):1219-1231. PubMed ID: 32996395
[TBL] [Abstract][Full Text] [Related]
20. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
